
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-04-05-2017
- Volume 12
- Issue 4
JRS Pharma Adds Povidone Product Line
Excipient manufacturer adds three tablet binding and disintegration products.
JRS Pharma announced the expansion its line of excipients for tablet binding and disintegration with a Feb. 28, 2017 press statement about a povidone product line that features Vivapharm PVP (povidone) wet binder, Vivapharm PVP/VA 64 (copovidone) tablet binder, and Vivapharm PVPP (crospovidone) to facilitate disintegration performance.
The company reports that the excipients are manufactured in a GMP and ISO 9001 compliant/certified production facility and comply with current compendial requirements in the European, US, and Japanese.
The company reports that it conducts on-site quality checks and final quality control and release in the Analytical Competence Center at the JRS Pharma facilities in Germany.
The company reports that it conducts on-site quality checks and final quality control and release in the Analytical Competence Center at the JRS Pharma facilities in Germany. The products will be warehoused in the JRS PHARMA central logistics center in Germany and the USA, thus enabling ease and speed of delivery.
Source:
Articles in this issue
over 8 years ago
Seeking Solutions for Oral Delivery of Biologic APIsover 8 years ago
Should More Pharma Products be Made in the USA?over 8 years ago
Technology to the Rescue for Data Integrity Challenges?over 8 years ago
Putting GS1’s EPCIS Standards to the Testover 8 years ago
RSSL Expands Particle Characterization Capabilitiesover 8 years ago
Permira Funds to Acquire LSNEover 8 years ago
Butterworth Laboratories Expands UK Lab Operationsover 8 years ago
Eurofins Scientific Invests in New UK Facilityover 8 years ago
Hitachi Chemical Purchases PCT From Caladrius BiosciencesNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





